Thrombin was reported to be a potent angiogenic factor both in vitro and in vivo and many of the cellular effects of thrombin may contribute to activation of angiogenesis.
Introduction
The frequency of blood coagulation in cancer patients, known for more than 130 years, is supported by clinical, laboratory and histopathological evidences. This is explained at the molecular and cellular level by the thromboplastic activity of circulating tumor cells, the existence of "a cancer coagulative factor", the activation of factor X, the generation of prothrombinase by tumor cells and the encircling of cancerous tissue by fibrin deposits (38, 50) . In addition, the possibility of a relation between blood clotting mechanisms and tumor progression and development of metastases was postulated as early as 1878 by Billroth (7) based on the observation that cancer cells exist within thrombi. This finding was interpreted as evidence that tumor cells spread by thromboembolism. More recently large epidemiological studies provided evidence that the standardized incidence ratio for certain types of cancer is as high as 6.7 within a year following a thromboembolic episode (3, 41) . This clinical data are in line with animal experiments where thrombin-treated B16 melanoma cells show a dramatic increase in their metastatic potential in the lung of rats (37). These observations have led to experimental use of heparin, aspirin and warfarin for the prevention and treatment of tumors in animal models and humans (50, 23) .
We have proposed earlier (47, 32) that the tumor promoting effect of thrombin/thrombosis may be related to our finding that thrombin is a potent promoter of angiogenesis, a process essential for tumor growth and metastasis. The angiogenic action of thrombin was shown to be receptor-mediated and independent of fibrin formation. The importance of thrombin and its receptors in embryonic development and angiogenesis is also supported by the findings of Griffin et al., (21) showing that the expression of protease activated receptor-1m (PAR-1) by endothelial cells rescues the fetal vessel fragility and bleeding of mouse embryo engineered to lack PAR-1. Recently we have shown that thrombin has a synergistic effect with the vascular endothelial growth factor (VEGF) by upregulating its receptors in cultured endothelial cells (46) . This, in connection to data showing that thrombin increases the secretion of VEGF from human prostate cancer cells (33) may result in mutual stimulation of endothelial and cancer cells for activation of angiogenesis and tumor progression. The role of thrombin receptors in angiogenesis and tumor progression is also supported by the findings of Even-Ram et al. (19) . They showed that the metastatic ability of human breast cancer cells is related to the number of thrombin receptors on these cells.
In this paper we present evidence that thrombin interacts with α ν β 3 integrin at the molecular and cellular level in endothelial cells. Integrin α ν β 3 is known to be expressed in vascular cells during angiogenesis and remodeling and in tumor cells where it contributes to malignant phenotype (18) . We demonstrate that thrombin-treatment of endothelial cells upregulates the expression of mRNA and protein of α ν β 3 integrin. This has as a result the potentiation of cell migration toward vitronectin, the α ν β 3 ligand. In addition we show that immobilized thrombin, like vitronectin, can serve as a ligand for α ν β 3 integrin.
This interaction of thrombin with α ν β 3 is shown to be of functional significance in vitro and in vivo. Immobilized thrombin facilitates endothelial cell attachment, migration and survival via α ν β 3 integrin interaction. In addition, we show that α ν β 3 integrin is involved in the thrombin-promoting angiogenesis in chick chorioallantoic membrane system.
Methods
Endothelial Cell Culture. HUVECs were obtained by established methods (25) from freshly delivered umbilical cords from caesarean births. Cells were cultured as described previously (46) and were used for experiments from passages 3-5. Chick Chorioallantoic membrane assay. The in vivo chick chorioallantoic membrane (CAM) angiogenesis model was used as described previously (31). Briefly, biochemical evaluation of angiogenesis was performed by determining the extent of collagenous protein biosynthesis in the CAM lying directly under the discs applied at day 9 of chick embryo development. Both control and test discs contained radiolabeled proline (0.5μCi/disc) and test disc contain also thrombin or cRGD or cRAD peptides or the combination. After 48 hours, the tissue under the discs was subjected to collagenase
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Results
Thrombin upregulates α ν β 3 mRNA and protein levels in HUVECs. We employed a sensitive quantitative RT-PCR technique to examine β 3 gene expression in HUVECs.
Primers for β 3 and GAPDH were chosen so that they would correspond to the regions where sequence homologies between the two primers are relatively low and would generate products of differing lengths. This allowed us to perform RT-PCR with the housekeeping gene GAPDH into the same reaction tubes with β 3 . Results presented in this report show that each set of primers worked well in specifying their corresponding mRNA. Single bands at about 284bp and 967bp were obtained for β 3 and GAPDH mRNA, respectively. Titration curves of RT-PCR products have been employed for determining the quantitative range in which the reactions proceeded exponentially (Fig.   1A ). Signal intensities of the products obtained were plotted as functions of RNA template amount and cycle number. Thus, we established the optimal conditions for RT-PCR, which were performed with 500ng of total RNA for 26 cycles. As shown in figure   1B , treatment of HUVECs with thrombin (1.0 IU/ml) resulted in an significant increase in the message for β 3 as compared with untreated cells. The upregulation of β 3 mRNA expression was evident 8 hours after thrombin stimulation. In addition, thrombin increased β 3 mRNA in a dose-dependent fashion. As shown in figure 1C , thrombin at 1 IU/ml increased β 3 mRNA expression to maximal levels. At 3 IU/ml, the stimulatory effect of thrombin declined to control levels. This bell-shaped effect of thrombin is observed in many of the cellular actions of thrombin including angiogenesis (47) . The specificity of thrombin was examined with the use of hirudin, which inhibits thrombin by binding both the catalytic and the anion-binding exocite. When hirudin (1 IU/ml) combined with thrombin (1 IU/ml) the thrombin-upregulating effect was abolished (Fig. 1D ). In addition, DIP-thrombin, which is catalytically inactive, had no any effect on β 3 mRNA levels (Fig. 1D ).
To determine whether the increase in β 3 mRNA was accompanied by an increase in protein synthesis, total endothelial cell lysates were immunoprecipitated using the anti-α ν β 3 mouse monoclonal antibody (LM609), which recognises human α ν β 3 integrin.
Immunoprecipitates were electrophoresed, transferred onto nitrocellulose membranes and immunoblotted with mouse monoclonal anti-β 3 antibody. A major band of about 95 kDa was detected. (Fig.1E) . After 24 hours of thrombin treatment, β 3 protein increased by about 94% over that of control (Fig.1E) . No signal was detectable if the antibodies used were pre-adsorbed with purified α ν β 3 protein, thus demonstrating the specificity of the band (data not shown).
The transduction mechanisms involved in the upregulation of α ν β 3 by thrombin and the participation of thrombin receptors are under study.
Endothelial cell adhesion on immobilized thrombin is mediated by ανβ3 integrin.
The upregulation of α ν β 3 by thrombin raises the question whether this thrombin-induced angiogenic phenotype of endothelial cells is manifested in other integrin-mediating effects related to angiogenesis such as attachment, migration and survival. Quantitative cell attachment assays were used to characterize the endothelial cell-thrombin interactions. As shown in figure 2A , immobilized thrombin supported endothelial cell adhesion in a concentration-dependent manner up to 1 μg/well. Above this concentration we observed the characteristic bell shape curve, known to occur in many of the action of thrombin. DIP-thrombin (the chemically inactivated thrombin at the active site) also increased cell attachment when immobilized on a solid surface. This excluded the involvement of the catalytic site of thrombin and the requirement for a proteolytic activation of thrombin receptors on endothelial cells. Furthermore, it was demonstrated that cell attachment on immobilized thrombin or DIP-thrombin was α ν β 3 -dependent.
When HUVECs were pretreated with 10μg/ml of LM609 antibody or 10 μg/ml of cRGD the attachment of endothelial cells on thrombin or DIP-thrombin was abolished (Fig. 2B) .
The inactive cRAD peptide had no effect (Fig. 2B) .
Immobilized thrombin promotes α ν β 3 -dependent endothelial cell migration. The α ν β 3 integrin is known to have a critical role in cell migration and survival (28, 34).
Furthermore, α ν β 3 antagonists have been shown to exert their anti-angiogenic effects in vivo by blocking survival signals mediated by this integrin (8, 44) . In view of the above findings, we examined whether thrombin affects α ν β 3 integrin-dependent endothelial cell migration and survival.
HUVECs readily migrated in a haptotactic boyden chamber assay through a microporous membrane toward immobilized thrombin or DIP-thrombin in dosedependent manner up to 1μg/filter. Above that concentration the stimulatory effect is diminished and we have the characteristic bell shape curve, known to occur in many of the action of thrombin (Fig.3A) . This migration was completely blocked by the anti-α ν β 3 antibody (LM609) or the cRGD peptide, but not by inactive cRAD peptide (Fig. 3B ).
Endothelial cell aptotactic migration is effectively prevented by the presence of thrombin in solution. As shown in figure 4A , soluble thrombin (1IU/ml) in lower chamber inhibits cell migration towards immobilized vitronectin and gelatin, two reported α ν β 3 integrin ligands (18, 14) . In similar experiments, anti-α ν β 3 antibody had the same inhibitory effect on endothelial cell motility toward vitronectin and gelatin (data not shown). On the other hand, when HUVECs preincubated with thrombin (1IU/ml) for 12 hours, were detached with EDTA and subsequently exposed to vitronectin or gelatin in chemotaxis analysis or in aptotactic cell motility assay, an increase of approximately 40% in migration was observed (Fig. 4B) . These findings are in agreement with the results presented in figure 1 and further support the notion that thrombin upregulates α ν β 3 expression and synthesis.
Immobilized thrombin promotes α ν β 3 -dependent endothelial cell survival. When
HUVECs were plated on immobilized BSA under serum-free conditions, significant levels of apoptosis were detected after 6 hours of incubation (Fig.5) . In contrast, and similar to what was reported previously (44) , plating of HUVECs on immobilized anti-α ν β 3 antibody protect cells from apoptosis (data not shown). We found that immobilized thrombin or DIP-thrombin mimics the effects of anti-α ν β 3 antibody and similarly promoted endothelial cell survival. Decreased levels of apoptosis were detected in cells adherent on plates coated with thrombin or DIP-thrombin (Fig. 5) . When soluble anti-α ν β 3 antibody or cRGD peptide was present a significant increase in the apoptosis of cells plated on immobilized thrombin was observed (Fig. 5) . On the contrary, the inactive peptide cRAD was without effect on thrombin-induced cell survival (Fig.5 ).
Thrombin binds to purified α ν β 3 integrin. We demonstrated a direct thrombin-α ν β 3 integrin interaction in a solid-phase ligand binding assay, using a commercially available purified α ν β 3 preparation. As shown in figure 6A , soluble α ν β 3 integrin can bind to immobilized thrombin or DIP-thrombin in a concentration-dependent manner and the binding was saturable. The specificity of the interaction was established by the fact that when α ν β 3 was neutralized by anti-α ν β 3 monoclonal antibody (LM609) or antagonized by cRGD peptide the binding was abolished. When EDTA was present the binding was also abolished suggesting that this process was cation-dependent (Fig. 6B) .
Integrin α ν β 3 is involved in thrombin-induced angiogenesis. We have used collagenous protein biosynthesis (CPB) as a biochemical index of angiogenesis (31). As shown in figure 7 , thrombin (1IU/disc) caused 100% increase of CPB, which is in line with our previous results (47) . The cRGD (100 μg/disc) peptide when used alone caused an inhibition of 30% compared to controls. The combination of thrombin with cRGD peptide decreased the thrombin-promoting angiogenesis to 28%. The inactive cRAD peptide had no effect. These results suggest that α ν β 3 antagonists can modulate the overall angiogenic effect of thrombin.
Discussion
In this report we have shown in endothelial cells that thrombin increases the mRNA and protein levels of α ν β 3 integrin in a time-and concentration-dependant fashion.
The transduction mechanisms involved for this upregulation are unknown. We are in the process of exploring these mechanisms involved and the requirement of thrombin receptors activation. Upregulation of α ν β 3 by thrombin has also been demonstrated previously in human colon adenocarcinoma cells (11) and in cultured smooth muscle cells (43). Furthermore, it has been shown that thrombin induces adhesion of tumor cells, neutrophils and monocytes to endothelial cell by increasing the expression of the integrin α ΙΙb β 3 in these cells (48, 36, 27 ).
We have also demonstrated that thrombin serves as a ligand to α ν β 3 . In a cell-free system immobilized thrombin binds to purified human α ν β 3 integrin. Biochemical evaluation of angiogenesis in vivo was performed by determining the extent of collagenous protein biosynthesis in the CAM lying directly under the discs applied at day 9 of chick embryo development. Both control and test discs contained radiolabeled proline (0.5μCi/disc) and test disc contain thrombin (1 IU/disc) or cRGD peptide (100 μg/disc) or cRAD (100 μg/disc) peptide or the combinations as indicated. For each egg, collagenous protein biosynthesis (CPB) under the disc containing the test material was expressed as % of that under the control disc in the same egg. In each group were used at least 12 eggs. Results are presented as mean % of control ± SE. **P<0.05, ***P<0.01. 
